Reduced Olfactory Bulb Volume Accompanies Olfactory Dysfunction After Mild SARS-CoV-2 Infection: The Hamburg City Health Study COVID Program

- 5 Marvin Petersen, MD^{a#}; Benjamin Becker, MD^{b#}; Maximilian Schell^a, Carola Mayer^a,
- 6 Felix L. Nägele^a, Elina Petersen, MSc^{c,d}; Raphael Twerenbold, MD^{c,d,e,f}; Götz
- 7 Thomalla, MD^a; Bastian Cheng, MD^a; Christian Betz, MD^b, Anna S. Hoffmann, MD^b
- 8 ^a Department of Neurology, University Medical Center Hamburg-Eppendorf,
- 9 Hamburg, Germany

4

- ^b Department of Otorhinolaryngology and Head and Neck Surgery, University Medical
- 11 Center Hamburg-Eppendorf, Hamburg, Germany
- ^c Population Health Research Department, University Heart and Vascular Center,
- 13 Hamburg, Germany
- ^d Department of Cardiology, University Heart and Vascular Center, Hamburg,
- 15 Germany
- ¹⁶ ^e German Center for Cardiovascular Research (DZHK), partner site
- 17 Hamburg/Kiel/Luebeck, Hamburg, Germany
- ¹⁸ ^f University Center of Cardiovascular Science, University Heart and Vascular Center,
- 19 Hamburg, Germany
- 20
- 21 # These authors contributed equally

- 24
- 25
- 26
- 27 28
- 29
- 30 Total word count of main manuscript: 3000

31

32 Materials & Correspondence

- 33 Correspondence and requests for materials should be addressed to
- 34 Dr. med. Marvin Petersen
- 35 Department of Neurology
- 36 University Medical Center Hamburg-Eppendorf
- 37 Martinistraße 52, 20246 Hamburg, Germany
- 38 +4940-7410-59094

40 Key Points

- 41 **Question**: Is olfactory dysfunction associated with alterations of the olfactory bulb in
- 42 individuals who recovered from mild to moderate SARS-CoV-2 infection?
- 43 **Findings**: 17.5% of investigated individuals exhibited long term olfactory dysfunction.
- 44 Olfactory bulb volume was lower in individuals with post-acute olfactory dysfunction
- 45 and predicted long-term olfactory function.
- 46 **Meaning**: Our results demonstrate the link between olfactory function and olfactory
- 47 bulb integrity after SARS-CoV-2 infection, rendering olfactory bulb volume a
- 48 promising surrogate marker of long-term smelling outcomes in COVID-19.
- 49
- 50

51 Abstract

52 **Importance:** Olfactory dysfunction is a frequent sequel of SARS-CoV-2 infection.

53 Despite its prevalence, the SARS-CoV-2-related pathophysiology of olfactory

- 54 dysfunction remains not well understood.
- 55
- 56 **Objective**: Determine whether long-term olfactory dysfunction in mild to moderate
- 57 SARS-CoV-2 infection corresponds with structural alteration of the olfactory bulb.
- 58

59 **Design, Setting and Participants**: Data of non-vaccinated COVID-19 convalescents 60 recruited between 1st March and 31st December 2020 were analyzed. Within the 61 framework of the Hamburg City Health Study COVID Program, participants 62 underwent magnetic resonance imaging (MRI) and neuropsychological testing as 63 well as a structured questionnaire for olfactory function. In addition, olfactory function 64 was assessed at an additional timepoint between 15th March and 15th April 2022 65 including quantitative olfactometric testing with Sniffin' Sticks.

66

Exposure: SARS-CoV-2 infection confirmed by a positive polymerase chain reaction
test (PCR).

69

Main Outcomes and Measures: Primary study outcomes were olfactory dysfunction
 and the MRI-based measurement of olfactory bulb volume.

72

Results: This study included 233 individuals recovered from mainly mild to moderate
 SARS-CoV-2 infections (44.2% female, age [years], mean ± SD, 55.79 ± 7.25).
 Longitudinal assessment demonstrated a declining prevalence of olfactory

76 dysfunction from 67.1% at acute infection, 21.0% at baseline examination (mean ± 77 SD, 8.31 \pm 2.77 months post infection) and 17.5% at follow-up (mean \pm SD, 21.8 \pm 78 3.61 months post infection). Participants with post-acute olfactory dysfunction had a 79 significantly lower olfactory bulb volume [mm³] at scan-time than normally smelling 80 individuals (mean \pm SD, baseline: 40.76 \pm 13.08 vs. 46.74 \pm 13.66, f = 4.07, p = 81 0.046; follow-up: 40.45 \pm 12.59 vs. 46.55 \pm 13.76, f = 4.50, p = 0.036). Olfactory bulb 82 volume predicted olfactometric scores at follow-up (r_{sp} = 0.154, p = 0.025). 83 Performance in neuropsychological testing was not significantly associated with the 84 olfactory bulb volume.

85

Conclusions: Our work demonstrates the association of olfactory dysfunction and olfactory bulb integrity in a sample of individuals recovered from mainly mild to moderate COVID-19. Olfactory bulb volume was demonstrably lower in individuals with sustained olfactory dysfunction and predicted long-term smelling function longitudinally. Collectively, our results highlight olfactory bulb volume as a surrogate marker that may inform diagnosis and guide rehabilitation strategies in COVID-19.

93 Introduction

94

95 The coronavirus disease 2019 (COVID-19) pandemic, which is caused by severe 96 acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has affected societies 97 worldwide. Olfactory dysfunction is among the most common symptoms in COVID-19 with a reported prevalence of up to 85%.^{1–8} COVID-19 features olfactory dysfunction 98 99 in varying degrees – e.g., anosmia, hyposmia or parosmia – which occur often before the onset of respiratory symptoms.³ Compared to other COVID-19-related symptoms 100 101 like cough, fever or fatigue, olfactory dysfunction proved to be more predictive of SARS-CoV-2 infection.^{9,10} Despite its relevance, the understanding of the 102 103 pathophysiology of SARS-CoV-2-related olfactory dysfunction is still incomplete.

104

105 There is ongoing research in the mechanisms of COVID-19-related olfactory 106 dysfunction. Commonly, anosmia in the absence of rhinorrhea or nasal congestion is 107 described as an early symptom which suggests other causal mechanisms than a common cold with conductive deficits causing olfactory dysfunction.^{3,4,11,12} SARS-108 109 CoV-2 might affect the olfactory system at different breakpoints of its trajectory 110 ranging from disruption of sustentacular cells and olfactory sensory neurons situated in the olfactory mucosa to functional disarray of the olfactory cortex.^{13,14} Yet, there is 111 112 only vague understanding of how these aspects relate to clinical outcomes.

113

114 Magnetic resonance imaging (MRI) provides a promising avenue to investigate the 115 pathomechanistic substrates of olfactory dysfunction in SARS-CoV-2 infection in vivo. 116 Previous MRI studies put emphasis on the integrity of the olfactory bulb (OB) as a 117 structural correlate of olfactory function in general.^{15–17} Volume reduction of the OB 118 accompanies olfactory loss in conditions like acute or chronic rhinosinusitis and head

trauma.¹⁸ Abnormalities in psychophysical olfactory testing are demonstrably associated with OB volume alterations in health and disease.^{19–21} Furthermore, the duration and degree of olfactory loss is proportional to the OB volume.²² So far, studies relating OB volumetry and olfactory function in COVID-19 rely on case reports and small sample sizes yielding heterogeneous results.^{14,23–27} Therefore, further investigations are warranted.

125

Based on previous evidence, we hypothesized that olfactory dysfunction in COVID-126 127 19 corresponds with interindividual volumetric differences of the OB. To address this 128 hypothesis, we quantified the OB volume based on structural MRI and performed a 129 longitudinal assessment of olfactory function in a large sample of individuals recovered from mainly mild to moderate COVID-19. As affection of the olfactory 130 131 system might precede COVID-19-related neuropathology, we additionally probed for 132 a relationship of OB alterations and neuropsychological test score results in an 133 exploratory analysis. With this work we aimed to further the understanding of the 134 effects SARS-CoV-2 exerts on the olfactory system and thus deepen our insight in 135 the pathophysiology underlying the clinical sequelae of COVID-19.

136

137 Methods

138

139 Study population and clinical examination

140 In this work we investigated data from participants of the Hamburg City Health Study

- 141 (HCHS) Covid Program with available MRI data. A detailed description of the study
- design has been published separately.^{28,29} Our reporting complies with the
- 143 Strengthening the Reporting of Observational Studies in Epidemiology (STROBE)
- statement guidelines.³⁰ In brief, citizens of the city of Hamburg, Germany, were
- 145 considered for enrollment if they met two criteria: (1) a laboratory-confirmed positive

polymerase chain reaction (PCR) test for SARS-CoV-2, which was obtained between 146 1st March and 31st December 2020 but at least 4 months prior to study enrollment; (2) 147 148 age between 45 and 74 years at the time of inclusion. An invitation was issued upon identification via the clinical information system of the University Medical Center 149 150 Hamburg-Eppendorf or a response to a public call for participation. Recruited 151 participants underwent an extended study protocol of the Hamburg City Health Study 152 (HCHS): besides the standard HCHS work up including MRI and assessment of 153 cognitive function (Trail Making Test B, Word List Recall, Animal Naming Test, Mini 154 Mental State Exam), depressive symptoms (PHQ-9) and guality of life (EQ-5D), 155 participants were required to retrospectively report on disease severity and SARS-CoV-2-associated symptoms via a structured guestionnaire.³¹ The presented study 156 157 was only conducted based on the post-SARS-CoV-2 cohort – i.e., the matched 158 cohort of control subjects as described previously could not be leveraged as the required high-resolution T2-weighted MRI data was not available.^{28,29} To assess the 159 trajectory of olfactory function, participants were reinvited between 15th March and 160 15th April 2022. Follow-up investigations comprised a structured questionnaire 161 162 regarding olfactory function as well as olfactometric assessment via Sniffin' Sticks Screening 12 test by two trained otorhinolaryngologists (B.B., A.S.H.).^{32,33} The test 163 164 score ranges from 0 to 12 (0-6: anosmia, 7-10: hyposmia, 11-12: normosmia) and is 165 based on normative information derived from more than 1200 patients assessed with 166 Sniffin' Sticks Screening and olfactive evoked potentials. Eventually, information 167 about olfactory dysfunction from structured questionnaires was available for three 168 timepoints: (1) during the acute infection, (2) at the baseline investigation and (3) at 169 follow-up. MRI and neuropsychological testing were only performed during baseline examination. 170

171 Ethics approval

- 172 Written informed consent was obtained from all participants. The study was approved
- by the local ethics committee of the Landesärztekammer Hamburg (State of
- 174 Hamburg Chamber of Medical Practitioners, PV5131) and conducted complying with
- 175 the Declaration of Helsinki.³⁴

176 MRI acquisition

- 177 High-resolution 3D T2-weighted images were acquired at baseline on a 3T scanner
- 178 (MAGNETOM[™]Skyra, Siemens Healthineers, Erlangen, Germany) with the following
- sequence parameters: TR=3200 ms, TE=407 ms, 256 axial slices, ST=0.94 mm, and
- 180 IPR=0.9×0.9mm.

181 Olfactory bulb segmentation

- 182 We performed OB segmentation on high-resolution T2-weighted images leveraging a
- 183 novel fully-automated deep learning-based pipeline specifically designed for OB
- volumetry.³⁵ All resulting segmentations underwent visual quality assessment.
- 185 Exemplary segmentation results are illustrated in *figure 1* as well as *supplementary*
- *materials S1*. The summed volume of both OBs was used for further analysis.

187 Statistical analysis

- 188 OB volume and olfactometry scores were compared between individuals with and
- 189 without questionnaire-assessed olfactory dysfunction at different timepoints
- 190 employing analyses of covariance (ANCOVA). Multiple linear regression analysis was
- 191 performed for assessing the linear relationship of olfactometry scores, as well as
- 192 neuropsychiatric scores with OB volume. A further ANCOVA was performed to test
- 193 whether the OB volume at baseline differed between individuals with sustained
- 194 olfactory dysfunction at follow-up and those that recovered until then. The association
- 195 between the time interval from positive PCR to examination was assessed via

196	Spearman correlation. Age, sex and smoking behavior were included as covariates in
197	ANCOVAs and linear models as they represent potential confounders. ³⁶ Statistical
198	computations and plotting were performed in Python 3.9.7 harnessing matplotlib
199	(v.3.5.1), numpy (v.1.22.3), pandas (v.1.4.2), pingouin (v.0.5.1) and seaborn
200	(v.0.11.2). ^{37–41}
201 202 203	Results
204	Sample characteristics
205	Data from 233 HCHS Covid Program participants was available for primary analysis.
206	Nine subjects were excluded pre-analysis: 3 since they reported to have had
207	olfactory dysfunction before their SARS-CoV-2 infection, 3 because of a missing OB
208	and 3 because of erroneous segmentations. Thus, data from n=224 participants were
209	available for the final analysis. Sample characteristics are summarized in table 1. On
210	average participants were 55.79 \pm 7.25 (mean \pm SD) years old, 44.2% were female
211	and 5.4% were current smokers. 8.4% of participants were hospitalized due to
212	COVID-19.
213	Longitudinal trajectory of olfactory function

The baseline examination happened on average 253 days after the positive PCR test

215 prompting recruitment, the follow-up at 663 days. 143 participants were available at

follow-up. Of these, 67.1% (n=96) described olfactory dysfunction during the acute

217 phase of infection, 21.0% (n=30) at the baseline examination and 17.5% (n=25) at

follow-up (*figure 2a*). Assessment of olfactory dysfunction severity via the visual

analogue scale resulted in a coherent trajectory: 7.62 ±2.76 (acute infection), 3.79

220 ±1.78 (baseline), 2.96 ±2.10 (follow-up).

221 Olfactometry

222 To assess long term olfactory outcomes, olfactometry with the Sniffin' Sticks

223 Screening 12 test was performed on participants at follow-up. Olfactometry scores at

follow-up were 10.18 ±1.78 (mean ±SD). Participants with self-reported olfactory

- 225 dysfunction at the acute infection did not differ from normally smelling participants
- regarding olfactometry scores at follow-up (mean ±SD, 10.04 ±1.97 vs. 10.46 ±1.31,

227 $eta_p^2=0.01$, p=0.211; figure 2b). Yet, participants with olfactory dysfunction at baseline

had lower olfactometric scores than normally smelling individuals (mean ± SD, 8.67 ±

229 2.62 vs. 10.58 \pm 1.22, eta_p^2 =0.19, p<0.005) and the same applied for participants

230 impaired at follow-up (mean \pm SD, 8.40 \pm 2.74 vs. 10.56 \pm 1.22, eta_p^2 =0.22, p<0.005).

231 Olfactory bulb volume and olfactory function

232 The mean OB volume was 45.53 ±12.85 mm³. The ANCOVA yielded no significant

- 233 group difference in OB volume at acute infection between individuals with and
- without olfactory dysfunction (mean ±SD, 45.85 ±12.92 vs. 45.21 ±15.16, eta_p^2 =0.00,
- p=0.837; figure 2c). Individuals with self-reported sustained olfactory dysfunction at
- baseline and at follow-up had significantly lower OB volume than normally smelling

237 subjects at that time (mean ±SD, baseline: 40.76 ±13.08 vs. 46.74 ±13.66,

238 $eta_p^2 = 0.03$, p = 0.046; follow-up: 40.45 ±12.59 vs. 46.55 ±13.76, $eta_p^2 = 0.03$, p = 0.036).

- 239 In participants with olfactory dysfunction lower OB volume was accompanied by a
- shorter time-period between a positive PCR for SARS-CoV-2, signifying the timepoint
- of acute SARS-CoV-2 infection, and the baseline examination (r_{sp} =0.161, p=0.016;
- 242 figure 2d).

243 Longitudinal prediction of olfactory function

OB volume derived from MRI at baseline was significantly linearly associated with olfactometry scoring at follow-up (r_{sp} =0.154, p=0.025; *figure 2e*). Participants with

- 246sustained olfactory dysfunction at follow-up had lower OB volume at baseline (mean247 \pm SD, 40.64 \pm 12.83 vs. 47.58 \pm 12.58, eta_p^2 =0.06, p=0.018; *figure 2f*) than those that248had recovered by the time of reassessment.249**Clinical analysis**250To further explore potential clinical implications of our findings, correlations of OB251volume and neuropsychological cognitive test scores and psychiatric test scores
- were performed. To summarize, no significant associations of OB volume and scores

of the Trail Making Test B (r_{sp} =0.014, p=0.722), Animal Naming Test (r_{sp} =-0.090,

- 254 p=0.069), Word List Recall Test ($r_{sp}=-0.050$, p=0.587), Mini Mental State Exam ($r_{sp}=-$
- 255 0.025, p=0.689), PHQ-9 (r_{sp} =0.098, p=0.404) and EQ-5D (r_{sp} =-0.009, p=0.306) were
- found. Corresponding visualizations are displayed in *supplementary materials* S2.
- 257

259

258 **Discussion**

260 We report on an association of OB volume and olfactory dysfunction in a large 261 sample of mainly mildly to moderately affected COVID-19 convalescents. 262 Longitudinal assessment demonstrated sustained olfactory dysfunction up to two 263 years after acute infection. Participants suffering from olfactory dysfunction beyond 264 acute infection had a significantly lower OB volume at baseline than normally 265 smelling individuals. Moreover, OB volume was predictive for olfactometric 266 performance in the Sniffin' Sticks test 22 months after the acute infection as well as 267 for the binary outcome of recovery from olfactory dysfunction at follow-up. 268 Neuropsychological test performances were not significantly associated with OB 269 volume. Taken together, our findings suggest that lower volume of the OB may be a 270 promising surrogate marker of smelling function in COVID-19 at post-acute disease 271 stages.

272

273 Its frequency and the concomitant effects on quality of life render olfactory 274 dysfunction a burdensome symptom of COVID-19. Our 2-year longitudinal 275 assessment of olfactory function provided insights about time-dependent 276 development of these symptoms. At acute infection, the proportion of participants 277 reporting olfactory dysfunction was 67.1% which is coherent with previous study reports ranging from 30% to 85%.^{1-4,6,7} After the acute infection, the prevalence 278 279 decreased to 21% at the baseline examination (on average 253 days post infection) 280 and 17.5% at follow-up (on average 664 days post infection; figure 2a). These 281 numbers support previous literature finding high rates of long term olfactory dysfunction in COVID-19.42-44 Of note, a recent meta-analysis reports persistent 282 olfactory dysfunction in less patients (11.6%; 95% confidence interval 5.2% to 283 23.9%).⁴⁵ We attribute this difference to design differences with respect to our work: 284 285 the studies included in the meta-analysis also considered young adults (>18 years) 286 possibly exhibiting higher regenerative capacity as well as recent SARS-CoV-2 287 variants demonstrably affecting patient olfaction less severely than the wild type variant mainly prevalent at the pandemic onset.⁴⁶ Overall, these findings indicate that 288 289 although most former COVID-19 patients completely recover, subjective olfactory 290 dysfunction persisted in relevant proportion of individuals.

291

To assess long term olfactory outcomes, olfactometry with the Sniffin' Sticks Screening 12 test was performed at follow-up. Participants suffering from olfactory dysfunction beyond the acute infection, plausibly showed significantly lower olfactometry scores than normally smelling or recovering subjects (*figure 2b*). Collectively, our results support previous evidence of sustained olfactory dysfunction

in around 20% of patients underscoring the possible long lasting burden following a
 SARS-CoV-2 infection.^{6,43}

299

Olfactory dysfunction is demonstrably accompanied by lower OB volume in many otorhinolaryngological conditions like post-infectious olfactory disorder, head trauma as well as acute and chronic rhinosinusitis.¹⁸ In line with this notion, our work showed a lower OB volume in individuals with sustained olfactory dysfunction after the acute SARS-CoV-2 infection indicating COVID-19-related OB atrophy (*figure 2c*). Thus, our results corroborate previous reports derived from case studies and small samples suggesting lower OB volume in SARS-CoV-2-induced olfactory dysfunction.^{23–26}

307

308 Previous reports demonstrated an inverse correlation between OB volume and the 309 duration of symptoms in post-infectious olfactory disorder suggesting its predictive capacity.²² To further investigate this, we related the OB volume with olfactometry 310 311 scores which were acquired approximately 1 year after the MRI. Notably, the OB 312 volume predicted olfactometry scores at follow-up (figure 2e). Yet, the observed 313 correspondence was of a rather low degree, indicating that further determinants of 314 long-term olfactory dysfunction should be considered. Possibly, MRI assessment 315 closer to the acute infection would have resulted in the observation of stronger 316 effects. Furthermore, OB volume was higher in participants in which the smelling 317 sense fully recovered until follow-up compared to those with sustained olfactory 318 dysfunction (figure 2f). Hence, the OB volume appears to be a predictor of recovery 319 from olfactory dysfunction, i.e., potentially capturing the severity of damage SARS-320 CoV-2 exerts on the olfactory system. Interestingly, individuals exhibited higher OB 321 volume the longer the time interval between the positive PCR and the MRI was 322 (figure 2d). This might indicate that an increasing OB volume may reflect recovery of 14 323 olfactory function. However, longitudinal imaging assessment is warranted here. 324 Taken together, these findings suggest that a lower OB volume indicates more 325 severe disruption of the olfactory system and predict persistent olfactory dysfunction 326 in COVID-19 patients. Therefore, the OB might serve as a promising diagnostical 327 target for prognosis assessment and even therapeutical monitoring of olfactory 328 dysfunction in COVID-19.

329

330 There are multiple potential mechanisms that might explain the observed link

between olfactory dysfunction and OB dysintegrity. In the olfactory mucosa, olfactory

332 sensory neurons (OSN) – sensing molecular signatures as odor information – as well

as supporting epithelial cells (sustentacular cells) ensure proper sense of smell.

334 Sustentacular cells express angiotensin-converting enzyme 2 (ACE-2) and appear to

be a major infection target of the virus.^{13,47} As they support OSN in a glial-like

fashion, impairment of sustentacular cells is considered to contribute to COVID-19-

³³⁷ related olfactory dysfunction.⁴⁸ How OSN are affected by SARS-CoV-2 is

338 controversial. Discussed mechanisms are neurotropism, affection by an impaired

339 support system and damage caused by the immune response to the virus.^{13,48,49}

340 Recent analyses failed to detect signs of neurotropism and neural invasion through

341 SARS-CoV-2 challenging the notion of the olfactory system serving the virus as an

entry point.^{48,50,51} As the OB serves as a relay for projections from the OSN,

343 volumetric reductions might occur as an effect of indirect OSN affection - e.g., via

inflammation or microvasculopathy – rather than direct damage from the virus leading

to reduced tissue integrity.⁵¹ Taking the link between OB integrity and long-term

346 olfactory function into account, OB volume might serve as an indicator of severe

347 structural disruption of the olfactory system which corresponds with unfavorable

outcomes. Nonetheless, further longitudinal neuroimaging research is warranted tosupport this notion.

350

351 By now, COVID-19 is recognized to cause post-acute neurological and psychiatric 352 symptoms like executive dysfunction, fatigue, anxiety, depression and sleep 353 impairment.^{52–56} Coherent with these observations, a comprehensive MRI analysis on 354 COVID-19 convalescents from the UK Biobank has shown widespread gray matter 355 volume reductions in areas receiving projections from the olfactory cortex.⁵³ Its 356 evident exposition to deleterious SARS-CoV-2 effects renders the OB a candidate 357 indicator of COVID-19-related neuropathology beyond the olfactory system. Thus, we 358 tested whether the OB volume is associated with results of neuropsychological test scores. OB volume showed no significant association with tests of cognitive function 359 360 (Trail Making Test B, Word List Recall, Animal Naming Test), depressive symptoms 361 (Patient Health Questionnaire-9, PHQ-9) and quality of life (EQ-5D). Consequently, 362 pathology of the olfactory system might be disjunct to non-olfaction-related 363 neuropathology in SARS-CoV-2 infection. Nonetheless, our findings might be partially 364 attributable to the overall mild to moderate disease course captured in our sample 365 resulting in negative results. Further investigations of determinants of neurological 366 and psychiatric sequelae of COVID-19 are necessary.

367

The strengths of this work lie in its considerable sample size; high quality imaging and phenotypical data; a modern fully-automated MRI-based segmentation of the OB enabling volumetry at scale; olfactory assessment at different time points post infection, including quantitative olfactory testing (at follow-up) providing longitudinal information for up to 2 years. Yet, this study has some limitations. First, MRI acquisition and olfactometry with Sniffin' sticks were performed only at one timepoint, 16

374 which makes it difficult to completely address pre-infectious group differences. For 375 instance, our results could partially be explained by individuals with lower OB volume 376 being more susceptible to olfactory dysfunction caused by SARS-CoV-2 infection. 377 Previous work hypothesizes that smaller OB volume and pre-existing reduced 378 number of olfactory receptor neurons increased the patient's vulnerability to develop 379 post-infectious olfactory loss. With less functional tissue existing in the first place, 380 damage to existing sensory cells might lead to more pronounced olfactory dysfunction.⁵⁷ Here, evidence from future longitudinal studies is warranted. As more 381 382 severely impaired individuals might be more motivated and thus more likely to 383 participate in our study than the average population, our results could possibly be 384 influenced by our recruitment strategy. Lastly, the different SARS-CoV-2 strains appear to differ in terms of olfactory dysfunction frequency and intensity. Our study 385 386 lacks information about SARS-CoV-2 strains rendering it incapable to address interstrain differences. However, the investigation started at an early stage of the 387 388 pandemic most likely soothing the problem of different COVID-19 strains and 389 vaccinations as confounders.

390

392

391 **Conclusion**

In this work, we performed an assessment of OB volumetry as a neuroimaging marker of olfactory dysfunction in patients recovered from mainly mild to moderate COVID-19. By revealing an alteration of the OB in participants with olfactory dysfunction, our results highlight the relevance of the olfactory system in the overall pathophysiology of the disease. However, a connection between OB volume and neuropsychological signs of COVID-19 could not be established. Collectively, these results demonstrate that the OB is a promising target for assessment of olfactory

- 400 dysfunction in COVID-19 potentially facilitating diagnosis and informing therapy-
- 401 related decisions.

403 Acknowledgments

404	We describe con	tributions to the	paper	using the	CRediT	contributor	role taxonomy	'.
							,	

- 405 Conceptualization: M.P, A.S.H.; Data Curation: M.P., B.B., M.S., C.M., F.N., A.S.H.;
- 406 Formal analysis: M.P.; Funding acquisition: G.T, B.C, C.B., A.S.H.; Investigation:
- 407 M.P., B.B., M.S., C.M., F.N., E.P., R.T., G.T., B.C., C.B., A.S.H.; Methodology: M.P.;
- 408 Software: M.P.; Supervision: C.B, A.S.H.; Visualization: M.P.; Writing—original draft:
- 409 M.P., B.B.; Writing—review & editing: M.P., B.B., M.S., C.M., F.N., E.P., R.T., G.T.,
- 410 B.C., C.B., A.S.H.
- 411 Data access: M.P., B.B., and A.S.H. had full access to all the data in the study and
- take responsibility for the integrity of the data and the accuracy of the data analysis.

- The authors wish to acknowledge all participants of the Hamburg City Health Study
- and cooperation partners, patrons and the Deanery from the University Medical
- 416 Center Hamburg—Eppendorf for supporting the Hamburg City Health Study. Special
- 417 thanks applies to the staff at the Epidemiological Study Center for conducting the
- 418 study. The participating institutes and departments from the University Medical
- 419 Center Hamburg-Eppendorf contribute all with individual and scaled budgets to the
- 420 overall funding. The Hamburg City Health Study is also supported by Amgen, Astra
- 421 Zeneca, Bayer, BASF, Deutsche Gesetzliche Unfallversicherung (DGUV), DIFE, the
- Innovative medicine initiative (IMI) under grant number No. 116074 and the
- 423 Fondation Leducq under grant number 16 CVD 03., Novartis, Pfizer, Schiller,
- 424 Siemens, Unilever and "Förderverein zur Förderung der HCHS e.V.". The publication
- has been approved by the Steering Board of the Hamburg City Health Study.
- 426 GT has received fees as consultant or lecturer from Acandis, Alexion, Amarin, Bayer,
- 427 Boehringer Ingelheim, BristolMyersSquibb/Pfizer, Daichi Sankyo, Portola, and

- 428 Stryker outside the submitted work. The remaining authors declare no conflicts of
- 429 interest.
- 430 This work was supported by grants from the German Research Foundation
- 431 (Deutsche Forschungsgemeinschaft, DFG), Schwerpunktprogramm (SPP) 204 -
- 432 project number 454012190 and Sonderforschungsbereich (SFB) 936 project
- 433 number 178316478 Project C2 (M.P., C.M., G.T., and B.C.).
- 434 Data will be made available on reasonable request from any qualified investigator
- 435 after evaluation of the request by the Steering Board of the HCHS. Analysis code and
- documentation is publicly available on GitHub (https://github.com/csi-
- 437 hamburg/CSIframe/blob/main/pipelines/obseg/obseg.sh, https://github.com/csi-
- 438 hamburg/CSIframe/wiki/Olfactory-bulb-segmentation and https://github.com/csi-
- 439 hamburg/2022_petersen_ob_postcovid).

441 **References**

- 1. von Bartheld CS, Hagen MM, Butowt R. Prevalence of Chemosensory Dysfunction in
- 444 COVID-19 Patients: A Systematic Review and Meta-analysis Reveals Significant Ethnic
- 445 Differences. *ACS Chem Neurosci*. 2020;11(19):2944-2961.
- 446 doi:10.1021/acschemneuro.0c00460
- Butowt R, von Bartheld CS. Anosmia in COVID-19: Underlying Mechanisms and
 Assessment of an Olfactory Route to Brain Infection. *Neuroscientist*. 2021;27(6):582-603.
 doi:10.1177/1073858420956905
- Cooper KW, Brann DH, Farruggia MC, et al. COVID-19 and the Chemical Senses:
 Supporting Players Take Center Stage. *Neuron*. 2020;107(2):219-233.
 doi:10.1016/j.neuron.2020.06.032
- Lechien JR, Chiesa-Estomba CM, De Siati DR, et al. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. *Eur Arch Otorhinolaryngol*. 2020;277(8):2251-2261. doi:10.1007/s00405-020-05965-1
- 457 5. Eliezer M, Hautefort C, Hamel AL, et al. Sudden and Complete Olfactory Loss of Function
 458 as a Possible Symptom of COVID-19. *JAMA Otolaryngology–Head & Neck Surgery*.
 459 2020;146(7):674-675. doi:10.1001/jamaoto.2020.0832
- 460 6. Lechien JR, Chiesa-Estomba CM, Beckers E, et al. Prevalence and 6-month recovery of
 461 olfactory dysfunction: a multicentre study of 1363 COVID-19 patients. *J Intern Med*.
 462 2021;290(2):451-461. doi:10.1111/joim.13209
- 463 7. Agyeman AA, Chin KL, Landersdorfer CB, Liew D, Ofori-Asenso R. Smell and Taste
 464 Dysfunction in Patients With COVID-19: A Systematic Review and Meta-analysis. *Mayo*465 *Clinic Proceedings*. 2020;95(8):1621-1631. doi:10.1016/j.mayocp.2020.05.030
- Parma V, Ohla K, Veldhuizen MG, et al. More Than Smell-COVID-19 Is Associated With
 Severe Impairment of Smell, Taste, and Chemesthesis. *Chem Senses*. 2020;45(7):609 622. doi:10.1093/chemse/bjaa041
- 469 9. Moein ST, Hashemian SM, Mansourafshar B, Khorram-Tousi A, Tabarsi P, Doty RL. Smell
 470 dysfunction: a biomarker for COVID-19. *Int Forum Allergy Rhinol*. 2020;10(8):944-950.
 471 doi:10.1002/alr.22587
- 472 10. Menni C, Valdes AM, Freidin MB, et al. Real-time tracking of self-reported symptoms to
 473 predict potential COVID-19. *Nat Med*. 2020;26(7):1037-1040. doi:10.1038/s41591-020474 0916-2
- 475 11. Vaira LA, Deiana G, Fois AG, et al. Objective evaluation of anosmia and ageusia in COVID476 19 patients: Single-center experience on 72 cases. *Head Neck*. 2020;42(6):1252-1258.
 477 doi:10.1002/hed.26204

478 12. Ahmed AK, Sayad R, Mahmoud IA, et al. "Anosmia" the mysterious collateral damage of
479 COVID-19. *J Neurovirol*. Published online March 5, 2022. doi:10.1007/s13365-022-01060480 9

- 481 13. Meinhardt J, Radke J, Dittmayer C, et al. Olfactory transmucosal SARS-CoV-2 invasion as
 482 a port of central nervous system entry in individuals with COVID-19. *Nat Neurosci*.
 483 2021;24(2):168-175. doi:10.1038/s41593-020-00758-5
- 484 14. Esposito F, Mario Cirillo, Rosa De Micco, et al. Olfactory loss and brain connectivity after
 485 COVID -19. *Human Brain Mapping*. Published online January 27, 2022.
 486 doi:10.1002/hbm.25741
- Haehner A, Rodewald A, Gerber JC, Hummel T. Correlation of Olfactory Function With
 Changes in the Volume of the Human Olfactory Bulb. *Archives of Otolaryngology–Head & Neck Surgery*. 2008;134(6):621-624. doi:10.1001/archotol.134.6.621
- 490 16. Lu R, Aziz NA, Reuter M, Stöcker T, Breteler MMB. Evaluation of the Neuroanatomical
 491 Basis of Olfactory Dysfunction in the General Population. JAMA Otolaryngology–Head &
 492 Neck Surgery. 2021;147(10):855-863. doi:10.1001/jamaoto.2021.2026
- 493 17. Das S. Olfactory Bulb Volume—A Novel Preclinical Biomarker for Smell Loss and
 494 Neurodegenerative Disease. JAMA Otolaryngology–Head & Neck Surgery.
 495 2021;147(10):864-865. doi:10.1001/jamaoto.2021.2038
- Hummel T, Urbig A, Huart C, Duprez T, Rombaux P. Volume of olfactory bulb and depth
 of olfactory sulcus in 378 consecutive patients with olfactory loss. *J Neurol*.
 2015;262(4):1046-1051. doi:10.1007/s00415-015-7691-x
- 499 19. Rombaux P, Mouraux A, Bertrand B, Nicolas G, Duprez T, Hummel T. Retronasal and
 500 orthonasal olfactory function in relation to olfactory bulb volume in patients with
 501 posttraumatic loss of smell. *Laryngoscope*. 2006;116(6):901-905.
- 502 doi:10.1097/01.mlg.0000217533.60311.e7
- 20. Rombaux P, Weitz H, Mouraux A, et al. Olfactory function assessed with orthonasal and
 retronasal testing, olfactory bulb volume, and chemosensory event-related potentials.
 Arch Otolaryngol Head Neck Surg. 2006;132(12):1346-1351.
- 506 doi:10.1001/archotol.132.12.1346
- S07 21. Rombaux P, Martinage S, Huart C, Collet S. Post-infectious olfactory loss: a cohort study
 and update. *B-ENT*. 2009;5 Suppl 13:89-95.
- 22. Yao L, Yi X, Pinto JM, et al. Olfactory cortex and Olfactory bulb volume alterations in
 patients with post-infectious Olfactory loss. *Brain Imaging Behav.* 2018;12(5):1355-1362.
 doi:10.1007/s11682-017-9807-7
- 512 23. Chiu A, Fischbein N, Wintermark M, Zaharchuk G, Yun PT, Zeineh M. COVID-19-induced
 513 anosmia associated with olfactory bulb atrophy. *Neuroradiology*. 2021;63(1):147-148.
 514 doi:10.1007/s00234-020-02554-1

24. Altunisik E, Baykan AH, Sahin S, Aydin E, Erturk SM. Quantitative Analysis of the Olfactory
System in COVID-19: An MR Imaging Study. *AJNR Am J Neuroradiol*. 2021;42(12):2207-

- 517 2214. doi:10.3174/ajnr.A7278
- 518 25. Güney B, Bacaksızlar Sarı F, Özdemir MY, Çullu N, Doğan E, Togan T. Changes in olfactory
 519 bulbus volume and olfactory sulcus depth in the chronic period after COVID-19 infection.
 520 Acta Otolaryngol. 2021;141(8):786-790. doi:10.1080/00016489.2021.1946138
- 521 26. Tsivgoulis G, Fragkou PC, Lachanis S, et al. Olfactory bulb and mucosa abnormalities in
 522 persistent COVID-19-induced anosmia: a magnetic resonance imaging study. *Eur J* 523 *Neurol*. 2021;28(1):e6-e8. doi:10.1111/ene.14537
- 524 27. Frosolini A, Parrino D, Fabbris C, et al. Magnetic Resonance Imaging Confirmed Olfactory
 525 Bulb Reduction in Long COVID-19: Literature Review and Case Series. *Brain Sciences*.
 526 2022;12(4):430. doi:10.3390/brainsci12040430
- 28. Petersen EL, Goßling A, Adam G, et al. Multi-organ assessment in mainly nonhospitalized individuals after SARS-CoV-2 infection: The Hamburg City Health Study
 COVID programme. *European Heart Journal*. Published online January 6, 2022:ehab914.
 doi:10.1093/eurheartj/ehab914
- 29. Petersen M, Nägele FL, Mayer C, et al. Brain imaging and neuropsychological assessment
 of individuals recovered from mild to moderate SARS-CoV-2 infection. Published online
 July 9, 2022:2022.07.08.22277420. doi:10.1101/2022.07.08.22277420
- 30. von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational
 Studies in Epidemiology (STROBE) statement: guidelines for reporting observational
 studies. *Lancet*. 2007;370(9596):1453-1457. doi:10.1016/S0140-6736(07)61602-X
- 537 31. Petersen M, Nägele FL, Mayer C, et al. Brain network architecture constrains age-related
 538 cortical thinning. *NeuroImage*. 2022;264:119721.
 539 doi:10.1016/j.neuroimage.2022.119721
- 540 32. Hummel T, Whitcroft KL, Andrews P, et al. Position paper on olfactory dysfunction.
 541 *Rhinol Suppl.* 2017;54(26):1-30. doi:10.4193/Rhino16.248
- 542 33. Hummel T, Welge-Lüssen A. Assessment of olfactory function. *Adv Otorhinolaryngol.*543 2006;63:84-98. doi:10.1159/000093752
- 34. Petersen M, Frey BM, Schlemm E, et al. Network Localisation of White Matter Damage in
 Cerebral Small Vessel Disease. *Scientific Reports*. 2020;10(1):9210. doi:10.1038/s41598020-66013-w
- 547 35. Estrada S, Lu R, Diers K, et al. Automated olfactory bulb segmentation on high
 548 resolutional T2-weighted MRI. *NeuroImage*. 2021;242:118464.
 549 doi:10.1016/j.neuroimage.2021.118464
- 550 36. Fitzek M, Patel PK, Solomon PD, et al. Integrated age-related immunohistological
 551 changes occur in human olfactory epithelium and olfactory bulb. *J Comp Neurol*.
 552 2022;530(12):2154-2175. doi:10.1002/cne.25325

- 37. Caswell TA, Droettboom M, Lee A, et al. matplotlib/matplotlib: REL: v3.5.2. Published
 online May 3, 2022. doi:10.5281/zenodo.6513224
- 38. Harris CR, Millman KJ, van der Walt SJ, et al. Array programming with NumPy. *Nature*.
 2020;585(7825):357-362. doi:10.1038/s41586-020-2649-2
- 557 39. Reback J, McKinney W, jbrockmendel, et al. pandas-dev/pandas: Pandas 1.0.3. Published 558 online March 18, 2020. doi:10.5281/zenodo.3715232
- 40. Vallat R. Pingouin: statistics in Python. *JOSS*. 2018;3(31):1026. doi:10.21105/joss.01026
- 41. Waskom ML. seaborn: statistical data visualization. *Journal of Open Source Software*.
 2021;6(60):3021. doi:10.21105/joss.03021
- 42. Mendes Paranhos AC, Nazareth Dias ÁR, Machado da Silva LC, et al. Sociodemographic
 Characteristics and Comorbidities of Patients With Long COVID and Persistent Olfactory
 Dysfunction. JAMA Network Open. 2022;5(9):e2230637.
- 565 doi:10.1001/jamanetworkopen.2022.30637

43. Boscolo-Rizzo P, Hummel T, Hopkins C, et al. High prevalence of long-term olfactory,
gustatory, and chemesthesis dysfunction in post-COVID-19 patients: a matched casecontrol study with one-year follow-up using a comprehensive psychophysical evaluation. *Rhinology*. 2021;59(6):517-527. doi:10.4193/Rhin21.249

- 44. Lucidi D, Molinari G, Silvestri M, et al. Patient-reported olfactory recovery after SARSCoV-2 infection: A 6-month follow-up study. *Int Forum Allergy Rhinol*. 2021;11(8):12491252. doi:10.1002/alr.22775
- 45. Tan BKJ, Han R, Zhao JJ, et al. Prognosis and persistence of smell and taste dysfunction in
 patients with covid-19: meta-analysis with parametric cure modelling of recovery curves. *BMJ*. 2022;378:e069503. doi:10.1136/bmj-2021-069503
- 46. Klimek L, Hagemann J, Hummel T, et al. Olfactory dysfunction is more severe in wild-type
 SARS-CoV-2 infection than in the Delta variant (B.1.617.2). *World Allergy Organization Journal*. 2022;15(6):100653. doi:10.1016/j.waojou.2022.100653
- 47. Chen M, Shen W, Rowan NR, et al. Elevated ACE-2 expression in the olfactory
 neuroepithelium: implications for anosmia and upper respiratory SARS-CoV-2 entry and
 replication. *Eur Respir J*. 2020;56(3):2001948. doi:10.1183/13993003.01948-2020
- 48. Khan M, Yoo SJ, Clijsters M, et al. Visualizing in deceased COVID-19 patients how SARSCoV-2 attacks the respiratory and olfactory mucosae but spares the olfactory bulb. *Cell*.
 2021;184(24):5932-5949.e15. doi:10.1016/j.cell.2021.10.027
- 49. Clara B, Audrey SA, Ophélie AG, et al. *Neutrophils Initiate the Destruction of the Olfactory Epithelium during SARS-CoV-2 Infection in Hamsters*. Immunology; 2022.
 doi:10.1101/2022.03.15.484439

- 588 50. Khan M, Clijsters M, Choi S, et al. Anatomical barriers against SARS-CoV-2 neuroinvasion
- at vulnerable interfaces visualized in deceased COVID-19 patients. *Neuron*.
- 590 2022;110(23):3919-3935.e6. doi:10.1016/j.neuron.2022.11.007
- 591 51. Ho CY, Salimian M, Hegert J, et al. Postmortem Assessment of Olfactory Tissue
 592 Degeneration and Microvasculopathy in Patients With COVID-19. JAMA Neurol.
- 593 Published online April 11, 2022. doi:10.1001/jamaneurol.2022.0154
- 52. Paterson RW, Brown RL, Benjamin L, et al. The emerging spectrum of COVID-19
 neurology: clinical, radiological and laboratory findings. *Brain*. 2020;143(10):3104-3120.
 doi:10.1093/brain/awaa240
- 597 53. Douaud G, Lee S, Alfaro-Almagro F, et al. SARS-CoV-2 is associated with changes in brain
 598 structure in UK Biobank. *Nature*. Published online March 7, 2022:1-17.
 599 doi:10.1038/s41586-022-04569-5
- 54. Carfi A, Bernabei R, Landi F, for the Gemelli Against COVID-19 Post-Acute Care Study
 Group. Persistent Symptoms in Patients After Acute COVID-19. *JAMA*. 2020;324(6):603605. doi:10.1001/jama.2020.12603
- 55. Huang C, Huang L, Wang Y, et al. 6-month consequences of COVID-19 in patients
 discharged from hospital: a cohort study. *The Lancet*. 2021;397(10270):220-232.
 doi:10.1016/S0140-6736(20)32656-8
- 60656. Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of607COVID-19. Nature. 2021;594(7862):259-264. doi:10.1038/s41586-021-03553-9
- 57. Patterson A, Hähner A, Kitzler HH, Hummel T. Are small olfactory bulbs a risk for
 olfactory loss following an upper respiratory tract infection? *Eur Arch Otorhinolaryngol*.
 2015;272(11):3593-3594. doi:10.1007/s00405-015-3524-x

612 Figure captions

613 *Figure 1*: Exemplary 3D visualization of olfactory bulb segmentation results.

Volumetric visualization of the left and right olfactory bulb (highlighted) and

615 surrounding brain areas. a) coronal, anterior-posterior; b) axial, inferior-superior; c)

616 sagittal, right-left.

617 Figure 2: Association of olfactory bulb volume and olfactory function. a) Trajectory of 618 olfactory function along timepoints. Blue dots indicate proportion of individuals with 619 olfactory dysfunction. Gray dots show the average impairment as operationalized by 620 the visual analogue scale. b) Group differences of olfactometry scores at follow-up 621 between participants with and without olfactory dysfunction at different timepoints. As 622 found with respect to olfactory bulb volume, olfactometry scores at follow-up were 623 significantly lower in individuals that exhibited olfactory dysfunction during both 624 examination timepoints but not during the acute infection. c) Group differences of 625 olfactory bulb volume at baseline between participants with and without olfactory 626 dysfunction with respect to different timepoints. Olfactory bulb volume at baseline 627 was significantly lower in individuals that exhibited olfactory dysfunction during both 628 examination timepoints but not during the acute infection. d) Association of the time 629 interval from positive PCR to examination and olfactory bulb volume. A smaller 630 interval was significantly associated with lower olfactory bulb volume. e) Linear 631 associations between olfactory bulb volume and olfactometry scores. A low olfactory 632 bulb volume at baseline was significantly associated with a lower olfactometry score 633 at follow-up. f) Group differences of olfactory bulb volume between participants with 634 sustained olfactory dysfunction at follow-up and those with recovered olfaction to that 635 point. Olfactory bulb volume was significantly lower in participants with sustained olfactory dysfunction. Abbreviations: eta_n^2 = partial eta squared indicating the effect 636

- 637 size as provided by the analysis of covariance, p = p-value, r_{sp} = spearman
- 638 correlation coefficient, PCR = polymerase chain reaction, T1 = at baseline, T2 = at
- 639 follow-up.

640

642 Tables

643 Table 1. Characteristics of Post-SARS-CoV-2 Individuals

Demographics						
Age in years, mean ± SD	55.79 ± 7.25					
Female sex at birth, %	44.2					
Education in years, mean ± SD	15.83 ± 2.52					
Current smokers, %	5.4					
Allergic rhinitis, %	33.3					
Diabetes, %	4.4					
COVID-19						
Days between first positive SARS-CoV-2 PCR test	253.15 ± 84.46					
and baseline (T1), mean \pm SD						
Days between first positive SARS-CoV-2 PCR test	663.51 ± 109.74					
and follow-up (T2), mean \pm SD						
Hospitalization, %	8.4					
Olfaction and olfactory bulb volume						
Subjective olfactory dysfunction at acute infection, %	67.1					
Olfactory dysfunction severity (VAS), acute infection,	7.62 ± 2.76					
mean ± SD						
Subjective olfactory dysfunction, T1, %	21.0					
Olfactory dysfunction severity (VAS), T1, mean ± SD	3.79 ± 1.78					
Subjective olfactory impairment, T2, %	17.5					
Olfactory dysfunction severity (VAS), T2, mean ± SD	2.96 ± 2.10					
Olfactometry score, T2, mean ± SD	10.18 ± 1.78					
Olfactory bulb volume in mm ³ , T1, mean ± SD	45.53 ± 12.85					
Neuropsychological scores						
Trail Making Test B, T1, mean ± SD	69.96 ± 24.84					

Word List Recall Test, T1, mean \pm SD	8.51 ± 1.67
Animal Naming Test, T1, mean \pm SD	28.25 ± 6.05
Mini Mental State Exam, T1, mean ± SD	28.42 ± 1.24
Patient Health Questionnaire 9, T1, mean \pm SD	3.54 ± 3.69
EQ5D, T1, mean ± SD	80.74 ± 14.42

644

645 *Abbreviations*: PCR = polymerase chain reaction, post-SARS-CoV-2 = individuals

646 who have recovered from a severe acute respiratory coronavirus type 2 infection, SD

estandard deviation, T1 = at baseline, T2 = at follow-up.















Normal Impaired Olfactory function, T1

d)



Normal Impaired Olfactory function, T2

 $eta_{p}^{2}: 0.22$

p : <0.005



Normal Impaired Olfactory function, T2

f)



Days from positive PCR to Examination; Acute infection \rightarrow T1



